The Role of Aspirin as Otoprotective Agent in Patients Receiving Amikacin Therapy

Abstract

Objective: To investigate and prove that aspirin
protects, or at least attenuates amikacin ototoxicity in
humans.
Method: This study was conducted in 60 patients that
completed all
requirements .The patients were divided into two
groups:
• Control group: receive placebo treatment.
• Drug–treated group: They receive aspirin
coated tablets (1.5gm/ day), 500mg 8 hourly.
Both groups had similar aspects regarding the gender,
age and weight. The duration of therapy was 7 days
and dosage of amikacin was 1gm/day (500mg 12
hourly).
Results: Comparison of Audiometry test in
Ear/Nose/Throat (E.N.T.) Department (Pure Tone
Audiometry) at 1000 Hertz (Hz), 2000 Hz, 4000 Hz,
and 8000 Hz showed significant differences between
mean Audiometry at 250Hz was significantly different
only at 8th and 15th day while at the frequency of 500Hz
the difference was significant at the 15thday only.
Conclusion: In present study, we had shown that
aspirin can protect the patients who are receiving
amikacin therapy from it' s ototoxicity.